**Online Resource 2. Summary of the method for drug price revision in Japan**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Classification | Item | Contents | Timing of review for price revision | Price  after revision |
| Regular price revision | | Price revision based on drug price survey | Once every 2 years until 2020,  once a year from 2021 | ↓ |
| Special rules  for price revision | Premium rewards for  innovative development | Development of orphan drugs | Irregular, review at the  time of regular price revision | → |
| Development request by regulatory agency |
| Drugs at premium prices because of usefulness or innovation |
| First-in-class drug |
| Same mechanism of action as the first-in-class drug |
| Price reduction for  long-listed drugs | Additional price reduction to the  price of the generic drugs in the case of long-listed drugs | Ten years after the launch of  the generic drug | ↓ |
| Market expansion-related re-pricing | Price reduction based on market expansion significantly  beyond prior projections | Timing of NHI price listing  (4 times a year) | ↓ |
| Other re-pricing | Re-pricing for dosage/regimen changes Re-pricing for additional indications | Timing of NHI price listing  (4 times a year) | ↓ |
| Premium rewards at  regular price revision | Premium rewards for pediatric indications | Irregular, review at the  time of regular price revision | → or ↑ |
| Premium rewards for orphan disease indications |
| Premium rewards for true clinical benefits |

NHI: National Health Insurance